SCHOTT Pharma AG & Co. KGaA: management transactions · Germany · BaFin

About SCHOTT Pharma AG & Co. KGaA

SCHOTT Pharma AG & Co. KGaA is a leading provider of drug containment solutions and delivery systems for injectable medicines. Listed on Xetra/Frankfurt (DAX/MDAX/SDAX) in Germany, the company holds a strong position in the pharmaceutical packaging value chain through a portfolio that includes prefillable syringes, cartridges, vials, ampoules, and related analytical, development, fill-and-finish, and regulatory services. SCHOTT Pharma describes itself as an end-to-end partner for pharmaceutical companies, biotech firms, and CDMOs, supplying both Type I borosilicate glass and advanced pharmaceutical polymer solutions. ([schott-pharma.com](https://www.schott-pharma.com/?utm_source=openai)) The company’s heritage is rooted in the broader SCHOTT group, which traces back more than 130 years to Otto Schott and his breakthroughs in specialty glass. SCHOTT Pharma was established as a standalone business in 2022 to accelerate growth and strengthen its capital-market profile. Its corporate headquarters are in Mainz, Germany, and its industrial footprint is global, with 16 GMP-compliant manufacturing sites across Europe, North America, South America, and Asia. The company states that it employs around 4,700 people worldwide, underscoring a sizeable international platform despite its specialist focus. ([schott-pharma.com](https://www.schott-pharma.com/en/about-us?utm_source=openai)) From a competitive standpoint, SCHOTT Pharma benefits from a reputation for technical leadership in a market supported by long-term structural demand drivers: biologics, GLP-1 therapies, ADCs, and increasing use of cold-chain and home-administration formats. The company highlights a customer base of more than 1,700 clients, including many of the world’s leading pharmaceutical manufacturers, and emphasizes one of the broadest product ranges in the market. A central strategic pillar is the expansion of higher-margin “high-value solutions,” which has consistently increased its contribution to revenue and profitability. ([schott-pharma.com](https://www.schott-pharma.com/en/news-and-media/media-releases/2022/schott-establishes-stand-alone-company-for-pharma-business-to-promote-further-growth?utm_source=openai)) Recent developments reinforce the investment case as a growth-and-margin story. In fiscal 2025, SCHOTT Pharma reported solid quarterly performance and later delivered full-year revenue of EUR 986.2 million with an EBITDA margin of 28.4%, while the share of high-value solutions rose to 57%. Management also guided for fiscal 2026 revenue growth of 2% to 5% at constant currencies and an EBITDA margin of around 27%. Governance updates in 2025 included the extension of CEO Andreas Reisse’s contract and the appointment of Reinhard Mayer as CFO, suggesting strategic continuity rather than disruption. ([schott-pharma.com](https://www.schott-pharma.com/en-gr/home/news-and-media/media-releases/2025/schott-pharma-delivers-on-full-year-revenue-and-profitability-targets?utm_source=openai))